Skye Bioscience, Inc. 8-K

What Happened
Skye Bioscience, Inc. (SKYE) announced in an 8-K filed May 15, 2026 that on May 13, 2026 it received a written notification from the Nasdaq Listing Qualifications Department stating the company is not in compliance with Nasdaq Global Market Rule 5450(b)(1)(A) because its stockholders’ equity was $9,011,804 as reported in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The notice does not immediately affect trading; SKYE common stock will continue to trade on Nasdaq under the symbol SKYE.

Key Details

• Nasdaq Rule: non-compliance with Listing Rule 5450(b)(1)(A) — minimum $10,000,000 stockholders’ equity required.
• Reported equity: $9,011,804 as of 3/31/2026 (per Form 10-Q).
• Timeline: Company has 45 calendar days (until June 29, 2026) to submit a plan; if accepted, Nasdaq may extend up to 180 days (until November 9, 2026) to demonstrate compliance.
• Next steps: Company is evaluating alternatives to regain compliance; if a plan is not accepted, the company may appeal and listing would remain through the appeal process.

Why It Matters
This notice signals that Skye currently falls short of Nasdaq’s minimum equity requirement, which poses a potential listing risk if the company cannot regain compliance within Nasdaq’s review periods. For investors, trading continues for now, but failure to remedy the deficiency or secure an accepted compliance plan could lead to delisting proceedings down the line. The filing provides concrete deadlines and options (plan submission, possible extension, and appeal) that will determine the near-term listing status.